Smith & Nephew SNATS (NYSE:SNN) Downgraded to “Hold” Rating by Kepler Capital Markets

Smith & Nephew SNATS (NYSE:SNN) was downgraded by equities researchers at Kepler Capital Markets from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Marketbeat reports.

Several other analysts have also recently commented on SNN. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Canaccord Genuity Group lowered their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Stock Up 2.0%

NYSE:SNN opened at $29.94 on Thursday. Smith & Nephew SNATS has a 12-month low of $28.40 and a 12-month high of $38.79. The company’s 50-day moving average is $31.47 and its two-hundred day moving average is $32.92. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion for the quarter. Research analysts expect that Smith & Nephew SNATS will post 2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC boosted its position in Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 387 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Smith & Nephew SNATS during the first quarter worth about $92,000. Parvin Asset Management LLC boosted its position in shares of Smith & Nephew SNATS by 8.5% in the first quarter. Parvin Asset Management LLC now owns 36,944 shares of the medical equipment provider’s stock worth $1,174,000 after buying an additional 2,894 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Smith & Nephew SNATS by 33.2% in the first quarter. EverSource Wealth Advisors LLC now owns 6,427 shares of the medical equipment provider’s stock valued at $204,000 after buying an additional 1,602 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Smith & Nephew SNATS by 6.7% during the 1st quarter. Royal Bank of Canada now owns 337,118 shares of the medical equipment provider’s stock valued at $10,713,000 after buying an additional 21,039 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.